Onco Actu du 28 septembre 2016

	3.1.1 Tabac - e-cigs
AACR Presents E-cigarette Webinar to Educate the Public [AACR] In recognition of the U.S Food and Drug Administration’s (FDA) ban on e-cigarette sales to youth in effect this past month, the American Association for Cancer Research (AACR) Tobacco and Cancer Subcommittee has released a new webinar, “E-cigarettes: Research, Public Health Concerns and Opportunities, and Regulations,” featuring key experts that will present current research on and the public health impact of e-cigarettes.
	5. Traitements
Iron nanoparticles prompt immune system to attack cancer, Stanford researchers find [Stanford Medicine] Somehow, the nanoparticles could work against cancer without any chemotherapy present. “It was an unanticipated finding, an accident.”
	5.10 Traitements - Essais
Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma [EndPoints] Amgen had been hoping to use this study to help justify the $10.4 billion acquisition of Onyx Pharmaceuticals back in 2013, after Onyx had pushed the treatment through to an approval.
Amgen's multiple myeloma drug falls short in late stage study [Reuters] Expectations of peak annual sales of about $2.3 billion for Kyprolis are now likely to cool, particularly since newly diagnosed patients constitute the largest market in terms of the number of patients and duration of therapy, some analysts said.
	5.12 Immunothérapies
Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup [Xconomy] Fortis is licensing the technology behind the drug program from the University of California, San Francisco, where it was developed in the lab of Bin Liu. Liu has identified a protein on the surface of tumor cells that the cells use to take in nutrients. Fortis declined to divulge more details about the target, but said Liu has submitted a paper on the topic to a scientific journal.
CICON16: Corrupted by Cancer [CRI] As the third session here at #CICON16 can attest, we now recognize that if we’re going to beat cancer, we’re going to have to tackle the tumor microenvironment along with it. f
CICON16: Cancer antigens and the development of personalized immunotherapy approaches [CRI] In his opening keynote, Philip D. Greenberg, Ph.D., who is head of immunology at the Fred Hutchinson Cancer Research Center and the University of Washington and a member of CRI’s Scientific Advisory Council (SAC), discussed his chosen antigens, WT1, CyclinA1, and mesothelin.
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints [CRI] The second session here at the International Cancer Immunotherapy Conference, taking place in New York City this week, discussed how current checkpoints fail, and explored the potential of other checkpoints that are being targeted to improve patient responses.
	5.12.1 Immunothérapies - partenariats
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214 [BMS] New collaboration will explore the potential benefits of combining Bristol-Myers Squibb’s anti-PD-1 antibody with Nektar’s CD122-biased agonist in five tumor types.
Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier [EndPoints] It’s easy to see why Bristol-Myers would be interested enough to foot half the costs of the upcoming work. Nektar has been running animal studies that demonstrated their drug’s ability to spur immune T cells to divide and activate, amping up an immune response.
Bristol-Myers And Nektar Cast Wide Net In Quest To Find The Right Immunotherapy Combo [Forbes] If a combo works, was it more because of drug A, drug B or something else? If it fails, is it because the drugs don’t work well together, or because they are being dosed in the wrong concentrations or wrong sequence? Will two potent drugs together cause too much toxicity? Can companies can play well together in the sandbox? What about the cost of two drugs versus one? The list of challenges goes on.
Bristol-Myers to test Opdivo with Nektar drug for several cancers [Reuters] The collaboration involves Nektar's NKTR-214, an experimental immuno-stimulatory therapy designed to increase the expression of PD-1 on immune cells.
	5.3 Traitements - FDA, EMA,...
From FDA expert to biotech insider: The drug industry thrives on the revolving door [STAT] “If individuals who work in industry are more informed about the regulatory process because of these employment transitions, that’s not a bad thing,” she said. “On the other hand, if former FDA staffers, in their current roles in industry, try to influence their former colleagues at the FDA, we should be concerned.”
The FDA's revolving door raises ethical questions [Modern Healthcare] They examined the post-FDA career paths of 55 hematology-oncology medical reviewers who approved and rejected drugs for the FDA from 2001 to 2010, discovering that 15 subsequently worked for or consulted to the biopharmaceutical industry.
When Drug Reviewers Leave The FDA, They Often Work For Pharma [Kaiser Health News] More than a quarter of the Food and Drug Administration employees who approved cancer and hematology drugs from 2001 through 2010 left the agency and now work or consult for pharmaceutical companies, according to research published by a prominent medical journal Tuesday.
	5.4 Traitements - Economie
Pegaspargase for treating acute lymphoblastic leukaemia [NICE] Pegaspargase, as part of antineoplastic combination therapy, is recommended as an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [NICE] Radium‑223 dichloride is recommended as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults, only if: - they have already had docetaxel or - docetaxel is contraindicated or is not suitable for them. The drug is only recommended if the company provides radium‑223 dichloride with the discount agreed in the patient access scheme.
Talimogene laherparepvec for treating unresectable metastatic melanoma [NICE] Talimogene laherparepvec is recommended, in adults, as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer [NICE] Necitumumab, in combination with gemcitabine and cisplatin, is not recommended within its marketing authorisation for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy.
Furor Over Drug Prices Puts Patient Advocacy Groups in Bind [NY Times] “It is a conflict of interest, because the interests of the pharmaceutical industry, from whom they are getting support, may be different from the interests of the patients,” said Dr. Michael Carome, the director of the Health Research Group at Public Citizen, a consumer advocacy group.
	5.6 ESMO
Merck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016 [PRNewswire] Preliminary results from combination study with avelumab in renal cell carcinoma, and updates on Phase II tepotinib program in non-small cell lung cancer, to be presented.
Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the European Society for Medical Oncology (ESMO) 2016 congress [Ipsen] Cabozantinib to be featured in eight presentations.
	6.1 Observation
1 in 5 emergency bowel cancer patients had symptoms before diagnosis [Cancer Research UK] The study found that ‘red flag’ symptoms were much more common in patients who were diagnosed via non-emergency routes, and that patients diagnosed as an emergency often did not display these symptoms strongly associated with bowel cancer.
Low cancer symptom awareness linked to lower chance of survival [Cancer Research UK] This is the first study in England to look at whether regional variation in cancer survival might be linked to regional variation in cancer symptom awareness and barriers to seeing the GP.
Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple-negative Breast Cancer Outcomes [AACR] Triple-negative breast cancer (TNBC) in African-American women is much more likely to lack the androgen receptor protein compared with TNBC in European-American women, and this may contribute to the racial disparity in survival outcomes among these two populations.
Concern over bowel cancer patients with symptoms year before diagnosis [The Guardian] A fifth of bowel cancer patients who received an emergency diagnosis in one year in England had characteristic symptoms the year before, suggesting their disease could have been caught earlier, researchers say.
	6.11 Patients
Many Cancer Caregivers Report Feeling Unprepared for Caregiving Challenges [NCI] Cancer caregivers devoted more hours to caregiving each week than did noncancer caregivers (32.9 hours versus 23.9 hours), the researchers found.
	6.7.3 DMP
Fixing electronic health records is good. Adding scribes is even better [STAT] While Bush’s company is trying to design ways to decrease the amount of time that clinicians spend working on the EHR, here’s a more immediate and practical solution: medical scribes. Let these trained professionals interact with the EHR while doctors interact with their patients.